Innovative Therapeutics Kaleido Biosciences is focused on developing novel therapies targeting the immune system via the gut microbiome, representing a unique and emerging frontier in biotechnology that offers opportunities for partnership and co-development with healthcare providers and research institutions.

Leadership & Growth Recent strategic appointments and leadership promotions indicate active development and scaling efforts, creating potential engagements around clinical trial partnerships, medical research collaborations, and clinical development services.

Partnership & Collaboration The company's partnership with Polygon and Janssen Biotech exemplifies its openness to strategic alliances, providing avenues for expanding technology integrations, blockchain solutions, and microbiome research collaborations with pharmaceutical and biotech entities.

Funding & Financials With funding totaling $60 million and annual revenues between $10 million and $25 million, Kaleido is a growing company that may be receptive to investment, contract manufacturing, or service partnerships to support its research and development initiatives.

Tech-Enabled Research Utilizing a modern tech stack including cloud services and digital tools, Kaleido is positioned as a biotech that leverages advanced technology solutions—offering opportunities for sales of digital infrastructure, cybersecurity, compliance, and data management solutions tailored to biotech research needs.